IMMX (IMMX) Stock Analysis
Verdict: HOLD
A strong $93.93M cash runway and $26 analyst targets propel IMMX, but zero revenue and clinical binary risk cap short-term probability.
Investment score: 54/100
The model views IMMX as a high-potential speculative clinical biotech backed by $93.93M in cash (~45 months runway) and strategic clinical ties with BeiGene, balanced by zero product revenue and trailing EPS misses.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| SLDB | -4.62 | 3.39 | 0.00 | -3.55 | — | 0.00 |
| FTH | -0.25 | 1.14 | -186.21 | -4.49 | — | 40.31 |
| SANA | -4.26 | 6.19 | 0.00 | -4.56 | — | 0.00 |
| AVTX | -3.55 | 1.64 | 15001.42 | -8.00 | — | -1700.56 |
| OLMA | -4.81 | 2.47 | 0.00 | -4.13 | — | 0.00 |